Yago Nieto, MD, PhD, a professor at the University of Texas MD Anderson Cancer Center, discusses the results of AFM13 in a phase 1 clinical trial for lymphoma.
AFM13, a CD30/CD16A bispecific antibody, activates natural killer (NK) cells to kill CD30-positive cells, according to the Nature paper that published the results. The investigators also reported in the paper that the overall response rate was 92.9% and complete response rates were 66.7%.
Reference
Nieto Y, Banerjee P, Kaur I, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025. doi:10.1038/s41591-025-03640-8.
